MOLI
Research type
Research Study
Full title
Mifepristone Outpatient Labour Induction
IRAS ID
1004485
Contact name
Mark Johnson
Contact email
Sponsor organisation
Chelsea and Westminster NHS Foundation Trust
Eudract number
2021-004860-93
Clinicaltrials.gov Identifier
Research summary
The number of women having an induction of labour is increasing and is currently used in 33% of pregnancies for a range of medical reasons. The majority of women are admitted to hospital to have their labour induced, using methods which are protracted and associated with a poor birth experience, making them both costly and unpopular. Further, current methods of outpatient induction are unsuitable, unsafe and/or have a poor acceptability. The COVID pandemic has driven a reduction in the number of face-to-face interactions taking place across all areas of medicine.
The study is a double blinded randomised study which will assess the efficacy and safety of Mifepristone for outpatient induction of labour. Mifepristone has the potential to be an ideal agent for the outpatient induction of labour: it does not require admission for its administration, it successfully induces labour in 30% of the cases and in those who do not labour, mifepristone makes the cervix more favourable and sensitises the uterus to the effects of prostaglandins and oxytocin, making a subsequent induction of labour shorter and more successful.
REC name
London - Fulham Research Ethics Committee
REC reference
22/LO/0072
Date of REC Opinion
21 Apr 2022
REC opinion
Further Information Favourable Opinion